Cover Story
Free
By Matthew Bin Han Ong
FDA's passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office said.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt - Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
- A clinic at Fred Hutch addresses sexual health needs of patients with breast cancer
Data indicate low adherence to ASCO guideline